Roche Group's Genentech says Avastin with chemo has been approved for specific advanced ovarian cancer treatment

Roche Group's Genentech said Tuesday that its Avastin drug had been approved by the Food and Drug Administration to treat a specific type of advanced ovarian cancer in combination with chemotherapy. The drug was given priority review for the disease, platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, and granted approval on the basis of two late-stage clinical trials, the company said. Roche shares dropped 19.7% year-to-date, compared with a 8.2% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.